Company: AZN
Filing Date: 2025-11-06
Form Type: 6-K
Source: 0001654954-25-012630
Chunk: 11

Company: ASTRAZENECA PLC
Filing Date: 2025-11-06
Form: 6-K
Chunk 11
---
 assets, including impairment reversals but excluding any charges relating to IT assets

- Other specified items, principally comprising acquisition-related costs and credits, which include the imputed finance charges and fair value movements relating to contingent consideration on business combinations, imputed finance charges and remeasurement adjustments on certain Other payables arising from intangible asset acquisitions, remeasurement adjustments relating to certain Other payables and debt items assumed from the Alexion acquisition and legal settlements

- The tax effects of the adjustments above are excluded from the Core Tax charge

Details on the nature of Core financial measures are provided on page 70 of the Annual Report and Form 20-F Information 2024 .

Reference should be made to the Reconciliation of Reported to Core financial measures table included in the Financial Performance section in this announcement.

Definitions

Gross Margin is defined as Gross Profit as a percentage of Total Revenue.

EBITDA is defined as Reported Profit before tax after adding back Net finance expense, results from Joint ventures and associates and charges for Depreciation, amortisation and impairment. Reference should be made to the Reconciliation of Reported Profit before tax to EBITDA included in the Financial Performance section in this announcement.

Operating margin is defined as Operating profit as a percentage of Total Revenue.

Net debt is defined as Interest-bearing loans and borrowings and Lease liabilities, net of Cash and cash equivalents, Other investments, and Net derivative financial instruments. Reference should be made to Note 3 'Net debt', included in the Notes to the interim financial statements in this announcement.

The Company strongly encourages investors and analysts not to rely on any single financial measure, but to review AstraZeneca's financial statements, including the Notes thereto, and other available Company reports, carefully and in their entirety.

Due to rounding, the sum of a number of dollar values and percentages in this announcement may not agree to totals.

Financial performance

Table 7: Reported Profit and Loss

|                                  | 9M 2025 | 9M 2024 |      % 
 Change |     | Q3 2025 | Q3 2024 |      % 
 Change |     |
|                                  |      $m |      $m | Actual | CER |      $m |      $m | Actual | CER |
| - Product Sales                  |  41,035 |  37,576 |      9 |   9 |  14,365 |  12,947 |     11 |   9 |
| - Alliance Revenue